Ronald Buckanovich, MD, PhD
Ward Rashidi MR, Mehta P, Bregenzer M, Raghavan S, Fleck EM, Horst EN, Harissa Z, Ravikumar V, Brady S, Bild A, Rao A, Buckanovich RJ, Mehta G. Engineered 3D Model of Cancer Stem Cell Enrichment and Chemoresistance. Neoplasia. 2019 Jul 9;21(8):822-836. doi: 10.1016/j.neo.2019.06.005. PubMed PMID: 31299607.
Madariaga A, Rustin GJS, Buckanovich RJ, Trent JC, Oza AM. Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers. Am Soc Clin Oncol Educ Book. 2019 Jan;39e152-e166. doi: 10.1200/EDBK_238755. PubMed PMID: 31099646.
Chandler C, Liu T, Buckanovich R, Coffman LG. The double edge sword of fibrosis in cancer. Transl Res. 2019 Jul;20955-67. doi: 10.1016/j.trsl.2019.02.006. PubMed PMID: 30871956; PMCID: PMC6545239.
Chefetz I, Grimley E, Yang K, Hong L, Vinogradova EV, Suciu R, Kovalenko I, Karnak D, Morgan CA, Chtcherbinine M, Buchman C, Huddle B, Barraza S, Morgan M, Bernstein KA, Yoon E, Lombard DB, Bild A, Mehta G, Romero I, Chiang CY, Landen C, Cravatt B, Hurley TD, Larsen SD, Buckanovich RJ. A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells. Cell Rep. 2019 Mar 12;26(11):3061-3075.e6. doi: 10.1016/j.celrep.2019.02.032. PubMed PMID: 30865894.
Belur Nagaraj A, Joseph P, Ponting E, Fedorov Y, Singh S, Cole A, Lee W, Yoon E, Baccarini A, Scacheri P, Buckanovich R, Adams DJ, Drapkin R, Brown BD, DiFeo A. A miRNA-Mediated Approach to Dissect the Complexity of Tumor-Initiating Cell Function and Identify miRNA-Targeting Drugs. Stem Cell Reports. 2019 Jan 8;12(1):122-134. doi: 10.1016/j.stemcr.2018.12.002. PubMed PMID: 30629937; PMCID: PMC6335585.
Coffman LG, Pearson AT, Frisbie LG, Freeman Z, Christie E, Bowtell DD, Buckanovich RJ. Ovarian Carcinoma-Associated Mesenchymal Stem Cells Arise from Tissue-Specific Normal Stroma. Stem Cells. 2019 Feb;37(2):257-269. doi: 10.1002/stem.2932. PubMed PMID: 30353617; PMCID: PMC6392140.
McLean K, Tan L, Bolland DE, Coffman LG, Peterson LF, Talpaz M, Neamati N, Buckanovich RJ. Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth. Oncogene. 2019 Feb;38(9):1576-1584. doi: 10.1038/s41388-018-0523-6. PubMed PMID: 30305729; PMCID: PMC6374186.
Iyengar M, O'Hayer P, Cole A, Sebastian T, Yang K, Coffman L, Buckanovich RJ. CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer. Oncotarget. 2018 Mar 20;9(21):15658-15672. doi: 10.18632/oncotarget.24585. PubMed PMID: 29644000; PMCID: PMC5884655.
Pearson AT, Ingram P, Bai S, O'Hayer P, Chung J, Yoon E, Jackson T, Buckanovich RJ. Sampling from single-cell observations to predict tumor cell growth in-vitro and in-vivo. Oncotarget. 2017 Dec 19;8(67):111176-111189. doi: 10.18632/oncotarget.22693. PubMed PMID: 29340046; PMCID: PMC5762314.
Samanta S, Tamura S, Dubeau L, Mhawech-Fauceglia P, Miyagi Y, Kato H, Lieberman R, Buckanovich RJ, Lin YG, Neamati N. Expression of protein disulfide isomerase family members correlates with tumor progression and patient survival in ovarian cancer. Oncotarget. 2017 Nov 28;8(61):103543-103556. doi: 10.18632/oncotarget.21569. PubMed PMID: 29262583; PMCID: PMC5732749.
Penn CA, Yang K, Zong H, Lim JY, Cole A, Yang D, Baker J, Goonewardena SN, Buckanovich RJ. Therapeutic Impact of Nanoparticle Therapy Targeting Tumor-Associated Macrophages. Mol Cancer Ther. 2018 Jan;17(1):96-106. doi: 10.1158/1535-7163.MCT-17-0688. PubMed PMID: 29133618; PMCID: PMC5752569.
